Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Chardan Capital

Chardan Capital started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report issued on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $50.00 target price on the stock.

A number of other research firms have also recently weighed in on PVLA. Stifel Nicolaus initiated coverage on Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price target on the stock. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Scotiabank began coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. Jones Trading started coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, TD Cowen initiated coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $44.43.

Palvella Therapeutics Stock Performance

PVLA traded down $0.64 during trading on Wednesday, reaching $21.16. 11,631 shares of the stock were exchanged, compared to its average volume of 65,994. The company has a market cap of $233.16 million, a PE ratio of -1.75 and a beta of 0.10. The business’s 50 day moving average price is $22.27. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27.

Hedge Funds Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC bought a new position in Palvella Therapeutics during the fourth quarter worth $125,000. Toronto Dominion Bank acquired a new position in shares of Palvella Therapeutics during the fourth quarter valued at about $159,000. Geode Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth about $171,000. Cresset Asset Management LLC acquired a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $251,000. Finally, Renaissance Technologies LLC bought a new stake in Palvella Therapeutics in the 4th quarter valued at about $256,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.